Jubilant Life Sciences receives ANDA approvals for Bupropion Hydrochloride

Posted On 18 Oct 2013
By :


Jubilant Life Sciences Ltd, an integrated Pharmaceuticals and Life Sciences Company announced today that it has received  Abbreviated New Drug Application (ANDA) approvals from the US Food and Drug  Administration (US FDA) for:

Bupropion Hydrochloride Extended-release Tablets USP (SR), 100 mg, 150 mg and 200 mg, the  generic version of GlaxoSmithKline’s antidepressant Wellbutrin SR (R)

Bupropion Hydrochloride Extended-release Tablets USP (SR), 150 mg, the generic version of  GlaxoSmithKline’s smoking cessation aid, Zyban (R)

The current total market size for these products as per IMS is US$ 518 Million per annum. We expect to launch these products in Q3 FY 14.

Read the source article at Share Market India

About the Author

Leave a Reply